June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
The long-term clinical efficacy of recombinant human nerve growth factor in the treatment of neurotrophic keratitis
Author Affiliations & Notes
  • alice bruscolini
    Sense Organs, Universita degli Studi di Roma La Sapienza Facolta di Medicina e Odontoiatria, Roma, Lazio, Italy
  • Marta Sacchetti
    Sense Organs, Universita degli Studi di Roma La Sapienza Facolta di Medicina e Odontoiatria, Roma, Lazio, Italy
  • Antonietta Moramarco
    Sense Organs, Universita degli Studi di Roma La Sapienza Facolta di Medicina e Odontoiatria, Roma, Lazio, Italy
  • Giuseppe Maria Albanese
    Sense Organs, Universita degli Studi di Roma La Sapienza Facolta di Medicina e Odontoiatria, Roma, Lazio, Italy
  • Alberto Cerini
    Sense Organs, Universita degli Studi di Roma La Sapienza Facolta di Medicina e Odontoiatria, Roma, Lazio, Italy
  • alessandro lambiase
    Sense Organs, Universita degli Studi di Roma La Sapienza Facolta di Medicina e Odontoiatria, Roma, Lazio, Italy
  • Footnotes
    Commercial Relationships   alice bruscolini, None; Marta Sacchetti, None; Antonietta Moramarco, None; Giuseppe Maria Albanese, None; Alberto Cerini, None; alessandro lambiase, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 728. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      alice bruscolini, Marta Sacchetti, Antonietta Moramarco, Giuseppe Maria Albanese, Alberto Cerini, alessandro lambiase; The long-term clinical efficacy of recombinant human nerve growth factor in the treatment of neurotrophic keratitis. Invest. Ophthalmol. Vis. Sci. 2021;62(8):728.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Topical recombinant human nerve growth factor (rhNGF) is FDA-approved to treat patients with neurotrophic keratitis (NK), but current clinical trial data only encompasses 1 year of follow up. We hypothesize that a single course of rhNGF can have a long-term, persistent effect on NK healing and related clinical parameters. Therefore, we evaluated the long-term efficacy of rhNGF in a retrospective, consecutive, observational case series from a single-center setting over a 4-year period.

Methods : A total of 18 patients with stage 2 or 3 NK received rhNGF 20 mcg/ml 6 times a day for 8 weeks. Lesion recurrence during follow-up was evaluated at 12, 24, 36, and 48 months. Clinical efficacy was measured by Cochet-Bonnet aesthesiometer (corneal sensitivity), Schirmer’s test (tear production), and Snellen chart [visual acuity (VA)] at baseline, end of treatment (8 weeks), and at 12, 24, 36, and 48 months after treatment was completed.

Results : Four patients experience recurrence during the study; 3 within the first 12 months and 1 within 36 months. Corneal sensitivity was significantly improved by the end of treatment (8 weeks) with improvements persisting throughout 48 months of follow-up (P<0.05). Both tear production and VA were also significantly improved by the end of treatment (8 weeks) and these effects persisted at 12, 24, and 36 months (P<0.05). Improvements in tear production and VA were also seen at 48 months; however, they were not statistically significant.

Conclusions : These results are consistent with our hypothesis that a single, 8-week treatment regimen of rhNGF can have long lasting clinical effects. The long-term clinical utility of rhNGF for the treatment of NK was demonstrated though the low rate of lesion recurrence along with improvements in corneal sensitivity, tear production, and VA over the course of 4 years.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×